The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

India's Glenmark Gets Arbitrator Nod to Sell HIV-Associated Diarrhea Drug

September 4, 2012

The International Center for Dispute Resolution has ruled that India's Glenmark Pharmaceuticals has the right to sell Crofelemer, its drug for HIV-associated diarrhea, in 140 countries. The medication was developed by Glenmark with U.S.-based partners Napo Pharmaceuticals and Salix Pharmaceuticals Ltd. Glenmark sought arbitration in the United States in December, after Napo terminated a three-party agreement that gave Glenmark exclusive distribution rights for Crofelemer in India and 139 other nations. In a statement, Glenmark said the ICDR found that Napo breached the agreement by revealing confidential information about manufacturing Crofelemer to Aptuit Laurus, another drugmaker. Glenn Saldanha, Glenmark's chair, said the ruling will permit the company "to further its commitment to working with relief agencies to distribute Crofelemer to affected populations."

Back to other news for September 2012

Adapted from:

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
See Also
HIV & You: Managing Gut Symptoms
More News and Research on Diarrhea

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: